This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Accentia Biopharmaceuticals, Inc.
Drug Names(s): Amphotericin B suspension
Description: SinuNase is an amphotericin B suspension that is self-administered into a patient’s nasal cavity. Amphotericin B is a polyene antimycotic drug, used intravenously in systemic fungal infections. Amphotericin B binds to sterols, preferentially to the primary fungal cell membrane sterol, ergosterol. This binding disrupts osmotic integrity of the fungal membrane, resulting in leakage of intracellular potassium, magnesium, sugars, and metabolites and then cellular death.
Accentia chose Amphotercin B in that it has very low absorption across mucus membranes, and in this rather unique situation the company does not need absorption of the drug into the sinus mucosa or the rest of the body. According to this disease model, the drug's desired site of action is confined to the mucus layer.
Deal Structure: In February 2004, Accentia acquired a license from the Mayo Foundation for Medical Education and Research that, as amended, gives Accentia the exclusive worldwide right to market and sell products based on Mayo Clinics patented treatment method using amphotericin B. Mayo Foundation holds an issued U.S. patent and a European Union counterpart patent application covering the use of intranasal antifungals for the treatment of Chronic Rhinosinusitis. It also holds a U.S. patent for the use of muco-administered antifungals for the treatment of asthma, and in December 2004, Accentia amended the license with the Mayo Foundation granting the company rights to this therapy using amphotericin B.
Additional information available to subscribers only: